Sotyktu (deucravacitinib) vs Bimzelx (bimekizumab-bkzx)
Sotyktu (deucravacitinib) vs Bimzelx (bimekizumab-bkzx)
Sotyktu (deucravacitinib) is an oral medication that works by selectively inhibiting the TYK2 enzyme, which is involved in the inflammatory process, and is approved for the treatment of moderate-to-severe plaque psoriasis in adults. Bimzelx (bimekizumab-bkzx), on the other hand, is a biologic therapy administered by injection, targeting both IL-17A and IL-17F cytokines, also for adults with moderate-to-severe plaque psoriasis. When deciding between the two, patients should consider factors such as the mode of administration, potential side effects, medical history, and the specific mechanisms of action, as well as discussing these with their healthcare provider to determine the most appropriate treatment for their condition.
Difference between Sotyktu and Bimzelx
Metric | Sotyktu (deucravacitinib) | Bimzelx (bimekizumab-bkzx) |
---|---|---|
Generic name | Deucravacitinib | Bimekizumab |
Indications | Plaque psoriasis | Plaque psoriasis, psoriatic arthritis |
Mechanism of action | Tyrosine kinase 2 (TYK2) inhibitor | Interleukin-17A and Interleukin-17F inhibitor |
Brand names | Sotyktu | Bimzelx |
Administrative route | Oral | Subcutaneous injection |
Side effects | Upper respiratory infections, headache, diarrhea, nausea, herpes zoster, etc. | Upper respiratory infections, oral candidiasis, headache, fatigue, injection site reactions, etc. |
Contraindications | None known specifically; caution in patients with active, chronic or recurrent infection | Known hypersensitivity to bimekizumab or excipients |
Drug class | Selective immunosuppressant | Monoclonal antibody |
Manufacturer | Bristol Myers Squibb | UCB S.A. |
Efficacy
Efficacy of Sotyktu (deucravacitinib) in Treating Psoriasis
Sotyktu, with the active ingredient deucravacitinib, is a novel oral medication approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. As a selective tyrosine kinase 2 (TYK2) inhibitor, Sotyktu works by modulating the immune response that contributes to the inflammation and plaque formation characteristic of psoriasis. Clinical trials have demonstrated that Sotyktu can lead to significant skin clearance. In the pivotal Phase 3 POETYK PSO-1 and PSO-2 trials, patients treated with Sotyktu showed a marked reduction in the Psoriasis Area and Severity Index (PASI) scores, which is a measure of the severity of psoriasis plaques, compared to those who received placebo.
The efficacy of Sotyktu was sustained over time, with a significant proportion of patients maintaining their PASI 75 response (75% reduction in PASI score) through 52 weeks of treatment. Moreover, many patients achieved a PASI 90 or PASI 100 response, indicating near-complete or complete clearance of skin lesions. The convenience of an oral administration route makes Sotyktu a valuable addition to the therapeutic arsenal for psoriasis, providing an alternative to injectable biologic treatments.
Efficacy of Bimzelx (bimekizumab-bkzx) in Treating Psoriasis
Bimzelx, with the active substance bimekizumab-bkzx, is a biologic medication approved for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. Bimzelx is a monoclonal antibody that selectively inhibits interleukin-17A and interleukin-17F, two key cytokines involved in the inflammatory process of psoriasis. Clinical studies, including the BE VIVID, BE READY, and BE SURE trials, have shown that Bimzelx can produce rapid and extensive skin clearance.
In these trials, a significant majority of patients treated with Bimzelx achieved PASI 90 and PASI 100 responses, indicating a high level of disease improvement. The onset of action was rapid, with some patients experiencing significant improvements as early as week 4. The efficacy of Bimzelx was maintained over a long-term period, with durable responses observed up to one year. The administration of Bimzelx is via subcutaneous injection, which may be preferred by some patients over oral medications or more frequent dosing schedules.
Regulatory Agency Approvals
Sotyktu
Bimzelx
Access Sotyktu or Bimzelx today
If Sotyktu or Bimzelx are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us